Trial Profile

Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inodiftagene-vixteplasmid (Primary)
Indications Bladder cancer; Carcinoma
Focus Therapeutic Use
Sponsors Anchiano Therapeutics Israel; BioCancell Therapeutics

Most Recent Events

09 Feb 2018 Results presented in a BioCancell Therapeutics Media Release.
09 Feb 2018 According to a BioCancell Therapeutics media release, final analysis of this trial were presented at the 2018 ASCO Genitourinary Cancers Symposium.
15 Nov 2017 According to a BioCancell Therapeutics media release, Patients are being followed for up to 2 years, and the median follow-up at the time of the analysis is approximately 18 months.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com